Brilinta patent expiration?

When does the Brilinta patent expire?

Brilinta, also known as ticagrelor, is a medication used to prevent blood clots in patients with acute coronary syndrome or stroke. The patent for Brilinta was initially granted to AstraZeneca in 2010 [1]. According to DrugPatentWatch.com, the Brilinta patent is set to expire in the United States in 2025, with the first patent expiring on November 27, 2025 [2]. However, the patent expiration date may vary depending on the country and region.

How long will Brilinta remain on the market after patent expiration?

After the patent expires, generic versions of Brilinta can be developed by other pharmaceutical companies. The first generic version of Brilinta was approved by the FDA in 2023, and it is expected to enter the market shortly after the patent expiration [3]. The entry of generic versions can lead to reduced prices for the medication, making it more accessible to patients.

What alternatives are available to patients when the Brilinta patent expires?

There is currently one approved generic version of Brilinta in the United States. As the generic version becomes more widely available, patients may have more affordable options for managing their condition. However, it is essential to note that generic medications must contain the same active ingredients as the brand-name medication and be manufactured according to the same quality standards.

References:

[1] AstraZeneca. (2010). Ticagrelor. United States Patent and Trademark Office.
[2] DrugPatentWatch.com. (2023). Brilinta (Ticagrelor) Generic Entry dates.
[3] FDA. (2023). FDA approves first generic version of Brilinta tablets.